$PBIO Pressure BioSciences’ BaroFold Platform Unleashes Hidden Growth Engine as Strong Demand for Protein Therapeutics Leverages PBI’s Protein Refolding Technology
https://www.accesswire.com/671146/pressure-bi...technology
Titans and Emerging Leaders of Biopharma Struggling with Protein Misfolding and Aggregation Issues that Threaten Enormous Revenue Potentials Are Turning to PBI's Uniquely Enabling BaroFold Solution
REMINDER: PBI to Participate in the Benzinga Virtual ALL ACCESS Investor Event Today at 11:20 am ET.
SOUTH EASTON, MA / ACCESSWIRE / November 4, 2021 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company"
, a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments, platform technologies, and related consumables for the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the strategic expansion of its patented BaroFold technology platform, with continued growth in services, sales and leasing.
Because of their high degree of specificity, proven efficacy, and minimal side effects, proteins have become the biological molecule of choice in therapeutic drug development. The global protein therapeutics market is expected to reach US $233 billion by 2027. Unfortunately, the manufacture of proteins as biological therapeutics is time-consuming, complex, and struggles with persistent challenges.
Dr. Alexander V. Lazarev, PBI's Chief Science Officer, said: "The biosimilars market for generic biotherapeutics is rapidly expanding worldwide and it demands lower costs of biotherapeutics. Biomanufacturing throughput and production costs can be slashed significantly if protein drugs are expressed in bacterial cells. Traditionally, bacterial systems were considered inferior to the cell cultures obtained from higher organisms due to higher incidence of certain issues, such as the formation of aggregates and the "misfolding" of polypeptides that fold in a specific pattern to give a protein its function. PBI's BaroFold™ technology platform, based on the innovative use of high pressure and protected by the Company's eight issued patent families, offers a uniquely gentle, exquisitely controllable, and cost-effective way to address these manufacturing challenges. To capitalize on this opportunity, PBI launched the BaroFold Biopharma Services Business ("BaroFold Services" in 2019."
Dr. Vera Gross, Director of Applications Development, commented: "The BaroFold platform can be applied to the development, production, and post-storage remediation of many different therapeutic proteins. The technology is scalable and practical for standard bioprocess environments. To put it simply, the BaroFold process uses physics where traditional processes use chemistry with arduous procedures and difficult cleanups. This means that the use of aggressive and toxic chemicals in the protein manufacturing process can be replaced in whole, or in part, by the use of high hydrostatic pressure. Thus, with this unique technology platform, we help our biopharma clients create and manufacture high quality novel protein therapeutics and biosimilars, while also lowering the cost of production and the environmental costs of chemical use and disposal. The benefits of the BaroFold platform are manifest in feedback from our customers and in their repeat business."
PBI's BaroFold Services business has grown significantly over the past two-plus years, from one customer in 2019, to two customers in 2020, to four in 2021. Current customers run the gamut from well-funded startups to multi-billion-dollar global biopharmaceutical companies. Such companies contract PBI to develop bioprocess steps utilizing the BaroFold Platform that can increase quality, reduce manufacturing costs, improve processing yields, and reduce the time to market for their planned protein-based therapeutics, each with sales potential from millions to a billion dollars, or more.
Mr. John B. Hollister, Director of Sales and Marketing, added: "The benefits of the BaroFold platform allow us to work with biopharma customers from the early stages of a protein drug's development. Initial contracts with the customer's R&D team will focus on showing Proof of Concept (POC). Once POC is demonstrated, we will continue to contract BaroFold Services as drug candidates move through successive stages of analysis and development: from pilot-scale processing, through volume scale-up, and finally to commercialization. Ultimately, the BaroFold platform will become Standard Operating Procedure for production of the protein therapeutic. From the biopharma's perspective, benefits include the commercialization of a drug that might otherwise never make it to market, as well as a potential increase in quality and decrease in manufacturing costs. From PBI's perspective, benefits include additional rounds of service fees, equipment sales/leases, and finally BaroFold license fees. For a commercially successful protein therapeutic, the licensing stream is expected to be extremely lucrative."
Mr. Hollister continued: "Recently it became evident that some biopharma companies developing protein-based therapeutics had libraries of protein drug candidates they would like PBI to evaluate, but it would be too costly to test them all through the BaroFold Service. Our due diligence indicated that if they had use of our small-scale BaroFold platform equipment, they could screen their library themselves and send to PBI only those that evidenced the most potential. We quickly set up a sale/leasing program to fulfill these needs. Recently, we leased two small-scale systems to a multi-billion-dollar biotech company and are in discussions with additional interested groups. Having now proven the concept, we believe this program will add greatly to the number of protein candidates utilizing our BaroFold services going forward, and that we will consequently see an increase in instrument/consumable revenue from biopharma companies in the protein therapeutic development space."
https://www.accesswire.com/671146/pressure-bi...technology
Titans and Emerging Leaders of Biopharma Struggling with Protein Misfolding and Aggregation Issues that Threaten Enormous Revenue Potentials Are Turning to PBI's Uniquely Enabling BaroFold Solution
REMINDER: PBI to Participate in the Benzinga Virtual ALL ACCESS Investor Event Today at 11:20 am ET.
SOUTH EASTON, MA / ACCESSWIRE / November 4, 2021 / Pressure BioSciences, Inc. (OTCQB
BIO) ("PBI" and the "Company" , a leader in the development and sale of innovative, broadly enabling, high pressure-based instruments, platform technologies, and related consumables for the worldwide life sciences, agriculture, food & beverage, and other key industries, today announced the strategic expansion of its patented BaroFold technology platform, with continued growth in services, sales and leasing. Because of their high degree of specificity, proven efficacy, and minimal side effects, proteins have become the biological molecule of choice in therapeutic drug development. The global protein therapeutics market is expected to reach US $233 billion by 2027. Unfortunately, the manufacture of proteins as biological therapeutics is time-consuming, complex, and struggles with persistent challenges.
Dr. Alexander V. Lazarev, PBI's Chief Science Officer, said: "The biosimilars market for generic biotherapeutics is rapidly expanding worldwide and it demands lower costs of biotherapeutics. Biomanufacturing throughput and production costs can be slashed significantly if protein drugs are expressed in bacterial cells. Traditionally, bacterial systems were considered inferior to the cell cultures obtained from higher organisms due to higher incidence of certain issues, such as the formation of aggregates and the "misfolding" of polypeptides that fold in a specific pattern to give a protein its function. PBI's BaroFold™ technology platform, based on the innovative use of high pressure and protected by the Company's eight issued patent families, offers a uniquely gentle, exquisitely controllable, and cost-effective way to address these manufacturing challenges. To capitalize on this opportunity, PBI launched the BaroFold Biopharma Services Business ("BaroFold Services"
in 2019." Dr. Vera Gross, Director of Applications Development, commented: "The BaroFold platform can be applied to the development, production, and post-storage remediation of many different therapeutic proteins. The technology is scalable and practical for standard bioprocess environments. To put it simply, the BaroFold process uses physics where traditional processes use chemistry with arduous procedures and difficult cleanups. This means that the use of aggressive and toxic chemicals in the protein manufacturing process can be replaced in whole, or in part, by the use of high hydrostatic pressure. Thus, with this unique technology platform, we help our biopharma clients create and manufacture high quality novel protein therapeutics and biosimilars, while also lowering the cost of production and the environmental costs of chemical use and disposal. The benefits of the BaroFold platform are manifest in feedback from our customers and in their repeat business."
PBI's BaroFold Services business has grown significantly over the past two-plus years, from one customer in 2019, to two customers in 2020, to four in 2021. Current customers run the gamut from well-funded startups to multi-billion-dollar global biopharmaceutical companies. Such companies contract PBI to develop bioprocess steps utilizing the BaroFold Platform that can increase quality, reduce manufacturing costs, improve processing yields, and reduce the time to market for their planned protein-based therapeutics, each with sales potential from millions to a billion dollars, or more.
Mr. John B. Hollister, Director of Sales and Marketing, added: "The benefits of the BaroFold platform allow us to work with biopharma customers from the early stages of a protein drug's development. Initial contracts with the customer's R&D team will focus on showing Proof of Concept (POC). Once POC is demonstrated, we will continue to contract BaroFold Services as drug candidates move through successive stages of analysis and development: from pilot-scale processing, through volume scale-up, and finally to commercialization. Ultimately, the BaroFold platform will become Standard Operating Procedure for production of the protein therapeutic. From the biopharma's perspective, benefits include the commercialization of a drug that might otherwise never make it to market, as well as a potential increase in quality and decrease in manufacturing costs. From PBI's perspective, benefits include additional rounds of service fees, equipment sales/leases, and finally BaroFold license fees. For a commercially successful protein therapeutic, the licensing stream is expected to be extremely lucrative."
Mr. Hollister continued: "Recently it became evident that some biopharma companies developing protein-based therapeutics had libraries of protein drug candidates they would like PBI to evaluate, but it would be too costly to test them all through the BaroFold Service. Our due diligence indicated that if they had use of our small-scale BaroFold platform equipment, they could screen their library themselves and send to PBI only those that evidenced the most potential. We quickly set up a sale/leasing program to fulfill these needs. Recently, we leased two small-scale systems to a multi-billion-dollar biotech company and are in discussions with additional interested groups. Having now proven the concept, we believe this program will add greatly to the number of protein candidates utilizing our BaroFold services going forward, and that we will consequently see an increase in instrument/consumable revenue from biopharma companies in the protein therapeutic development space."
